Skip to main content

Table 1 Baseline clinical characteristics

From: The effect of dapagliflozin treatment on epicardial adipose tissue volume

  Dapagliflozin (N = 20) Conventional therapy (N = 20) p value
Age (years) 68 ± 4 66 ± 6 0.30
Male/female (n) 16/4 14/6 0.48
Body weight (kg) 71.4 ± 14.4 69.5 ± 12.2 0.37
BMI 26.6 ± 4.6 25.0 ± 3.1 0.25
Hypertension 14 (70) 12 (60) 0.52
Smoking, ever 6 (30) 5 (25) 0.73
Lipid profile
 LDL (mg/dl) 91 ± 26 84 ± 20 0.44
 TG (mg/dl) 152 ± 92 151 ± 81 0.83
 HDL (mg/dl) 46 ± 14 40 ± 10 0.17
 TG/HDL 3.6 ± 2.1 3.7 ± 2.1 0.73
Glycemic marker
 HbA1c (%) 7.2 ± 0.6 7.4 ± 1.1 0.51
 FBS (mg/dl) 144 ± 41 136 ± 24 0.48
 HOMA-IR 2.6 ± 1.9 2.5 ± 1.8 0.79
 iHOMA 2%S 113 ± 94 134 ± 75 0.52
 Keton body (μmol/l) 126 ± 116 120 ± 105  
Adipose-associated marker
 EAT volume (cm3) 115 ± 22 108 ± 25 0.38
 TNF-α (pg/ml) 2.4 ± 0.7 2.2 ± 0.7 0.78
 PAI-1 (ng/ml) 42.2 ± 16.1 45.7 ± 14.6 0.41
 BNP (pg/ml) 82 ± 88 102 ± 129 0.62
 Alb/Cre ratio (mg/g CRE) 21 ± 39 38 ± 68 0.50
  1. Data are presented as mean ± SD or the number (percentage)
  2. LDL low density lipoprotein cholesterol, HDL high density lipoprotein cholesterol, HOMA-IR homeostatic model assessment insulin resistance, iHOMA-2 interactive 24-variable model homeostatic model assessment insulin resistance-2, EAT epicardial adipose tissue, TNF-α tumor necrotic factor-α, PAI-1 plasminogen activator inhibitor-1, BNP brain natriuretic peptide, Alb/Cre ratio albumin/creatinine ratio